| Identification | Back Directory | [Name]
2-Pyrimidinamine, 5-fluoro-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-N-[5-(1-piperazinylmethyl)-2-pyridinyl]- | [CAS]
2688098-02-2 | [Synonyms]
CDK4/6-IN-9
2-Pyrimidinamine, 5-fluoro-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-N-[5-(1-piperazinylmethyl)-2-pyridinyl]- | [Molecular Formula]
C22H23FN8 | [MOL File]
2688098-02-2.mol | [Molecular Weight]
418.47 |
| Hazard Information | Back Directory | [Uses]
CDK4/6-IN-9 (compound 10) is a selective CDK4/6 inhibitor with an IC50 of 905 nM for CDK6/cyclin D1. CDK4/6-IN-9 has?the?potential?for?multiple myeloma (MM)?research[1]. | [IC 50]
CDK6/cyclinD1: 905 nM (IC50); CDK4/cyclinD1 | [References]
[1] Kai Yuan, et al. Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma. Eur J Med Chem. 2022 Jan 15;228:114024. DOI:10.1016/j.ejmech.2021.114024 |
|
|